$FZMD
Fuse Medical, Inc. Stock $fzmd

$fzmd Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000156459022029139 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$4.537M	$4.668M	$4.554M
YoY Change	6.73%	-17.59%	2.56%
Cost Of Revenue	$1.482M	$1.724M	$1.625M
YoY Change	-20.41%	-22.34%	-12.34%
Gross Profit	$3.055M	$2.945M	$2.929M
YoY Change	27.88%	-14.53%	13.23%
Gross Profit Margin	67.34%	63.08%	64.32%
Selling, General & Admin	$1.709M	$1.423M	$3.215M
YoY Change	-44.08%	-29.62%	7.17%
% of Gross Profit	55.93%	48.32%	109.77%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$49.48K	$56.21K	$55.12K
YoY Change	2559.0%	263.46%	228.22%
% of Gross Profit	1.62%	1.91%	1.88%
Operating Expenses	$3.010M	$2.996M	$3.250M
YoY Change	-1.95%	-22.61%	7.72%
Operating Profit	$44.89K	-$51.62K	-$320.5K
YoY Change	-106.59%	-87.88%	-25.47%
Interest Expense	$46.99K	$36.53K	-$32.96K
YoY Change	-475.64%	127.61%	73.47%
% of Operating Profit	104.67%
Other Income/Expense, Net	-$46.99K	-$36.53K	-$32.96K
YoY Change	275.58%	-110.58%	73.46%
Pretax Income	-$2.098K	-$88.15K	-$353.4K
YoY Change	-99.7%	9.29%	-21.28%
Income Tax	$7.278K	$5.171K	$4.856K
% Of Pretax Income
Net Earnings	-$9.376K	-$93.32K	-$358.3K
YoY Change	-98.65%	9.17%	-20.97%
Net Earnings / Revenue	-0.21%	-2.0%	-7.87%
Basic Earnings Per Share	$0.00	$0.00	-$0.01
Diluted Earnings Per Share	-$133.40	-$1.327K	-$5.095K
COMMON SHARES
Basic Shares Outstanding	72.90M	70.32M	70.32M
Diluted Shares Outstanding			70.32M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$506.0K	$604.0K	$522.5K
YoY Change	-71.34%	-55.49%	-63.15%
Cash & Equivalents	$506.0K	$604.0K	$522.5K
Short-Term Investments
Other Short-Term Assets	$33.71K	$95.33K	$95.93K
YoY Change	-49.28%	56.02%	1.47%
Inventory	$9.851M	$9.357M	$9.264M
Prepaid Expenses
Receivables	$2.626M	$2.965M	$2.164M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.02M	$13.02M	$12.05M
YoY Change	1.23%	1.87%	-4.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$399.9K	$351.6K	$123.7K
YoY Change	4374.69%	3155.96%	807.41%
Goodwill	$1.973M	$1.973M	$1.973M
YoY Change	0.0%	0.0%
Intangibles	$1.224M	$1.256M	$1.289M
YoY Change	11.23%	12.9%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.167M	$6.031M	$5.727M
YoY Change	19.59%	15.42%	17.79%
TOTAL ASSETS
Total Short-Term Assets	$13.02M	$13.02M	$12.05M
Total Long-Term Assets	$6.167M	$6.031M	$5.727M
Total Assets	$19.18M	$19.05M	$17.77M
YoY Change	6.48%	5.8%	1.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.822M	$4.782M	$4.570M
YoY Change	9.38%	11.08%	37.45%
Accrued Expenses	$4.244M	$3.954M	$3.125M
YoY Change	39.71%	40.22%	15.87%
Deferred Revenue
YoY Change
Short-Term Debt	$2.395M	$2.590M	$2.062M
YoY Change	125.19%	143.59%	28.92%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.46M	$11.33M	$9.758M
YoY Change	34.68%	38.25%	27.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$200.0K
YoY Change	-100.0%	-100.0%	-42.36%
Other Long-Term Liabilities	$11.59M	$11.59M	$11.59M
YoY Change	-2.87%	-2.87%	-2.87%
Total Long-Term Liabilities	$11.59M	$11.59M	$11.79M
YoY Change	-8.22%	-5.6%	-3.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.46M	$11.33M	$9.758M
Total Long-Term Liabilities	$11.59M	$11.59M	$11.79M
Total Liabilities	$23.06M	$22.92M	$21.55M
YoY Change	9.05%	11.94%	8.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.077M	-$6.068M
YoY Change		32.86%
Common Stock	$2.205M	$2.201M
YoY Change		4.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.872M	-$3.866M	-$3.777M
YoY Change
Total Liabilities & Shareholders Equity	$19.18M	$19.05M	$17.77M
YoY Change	6.48%	5.8%	1.81%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$9.376K	-$93.32K	-$358.3K
YoY Change	-98.65%	9.17%	-20.97%
Depreciation, Depletion And Amortization	$49.48K	$56.21K	$55.12K
YoY Change	2559.0%	263.46%	228.22%
Cash From Operating Activities	$195.4K	$37.91K	$633.0K
YoY Change	214.82%	-66.77%	1043.78%
INVESTING ACTIVITIES
Capital Expenditures	-$97.82K	-$284.1K	-$138.8K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$97.82K	-$284.1K	-$138.8K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-195.6K	327.7K	-524.8K
YoY Change	-156.46%	-287.28%	-399.91%
NET CHANGE
Cash From Operating Activities	195.4K	37.91K	633.0K
Cash From Investing Activities	-97.82K	-284.1K	-138.8K
Cash From Financing Activities	-195.6K	327.7K	-524.8K
Net Change In Cash	-98.00K	81.52K	-30.71K
YoY Change	-124.0%	-233.81%	-113.33%
FREE CASH FLOW
Cash From Operating Activities	$195.4K	$37.91K	$633.0K
Capital Expenditures	-$97.82K	-$284.1K	-$138.8K
Free Cash Flow	$293.2K	$322.0K	$771.8K
YoY Change	372.45%	182.29%	1294.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M23D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M26D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M15D
	fzmd	Gain Loss On Payroll Protection Loan Extinguishment GainLossOnPayrollProtectionLoanExtinguishment	361400
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-529617
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9186
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70221566
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3431819
	fzmd	Net Payment Proceeds On Senior Secured Revolving Credit Facility NetPaymentProceedsOnSeniorSecuredRevolvingCreditFacility	-192599
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4500
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-197099
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-358281
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-3777256
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4102
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-93319
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3866473
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2112841
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	115948
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-453323
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70075
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-85480
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-2465621
	us-gaap	Profit Loss ProfitLoss	-451600
	us-gaap	Profit Loss ProfitLoss	-538803
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	144044
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32258
	us-gaap	Share Based Compensation ShareBasedCompensation	16946
	us-gaap	Share Based Compensation ShareBasedCompensation	186023
	fzmd	Provision For Bad Debts And Discounts ProvisionForBadDebtsAndDiscounts	-102595
	fzmd	Provision For Bad Debts And Discounts ProvisionForBadDebtsAndDiscounts	153517
	fzmd	Provision For Long Term Accounts Receivable ProvisionForLongTermAccountsReceivable	402200
	fzmd	Provision For Long Term Accounts Receivable ProvisionForLongTermAccountsReceivable	659442
	fzmd	Provisions For Slow Moving Inventory ProvisionsForSlowMovingInventory	-94595
	fzmd	Provisions For Slow Moving Inventory ProvisionsForSlowMovingInventory	-433505
	fzmd	Gain Loss On Payroll Protection Program Loan Extinguishment GainLossOnPayrollProtectionProgramLoanExtinguishment	361400
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-666843
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1222444
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	526213
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	897793
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	89410
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	36895
	fzmd	Increase Decrease In Long Term Accounts Receivable IncreaseDecreaseInLongTermAccountsReceivable	670332
	fzmd	Increase Decrease In Long Term Accounts Receivable IncreaseDecreaseInLongTermAccountsReceivable	1118958
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	320071
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1068299
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1055519
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	234789
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	670878
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	169418
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	422973
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-422973
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50806
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	169418
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	553190
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1187458
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	603996
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1356876
	us-gaap	Interest Paid Net InterestPaidNet	50796
	us-gaap	Interest Paid Net InterestPaidNet	21235
CY2022Q2	us-gaap	Goodwill Goodwill	1972886
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the interim unaudited condensed consolidated financial statements in accordance with GAAP, requires the Company to make estimates and assumptions that affect the Company’s reported amounts in the interim unaudited condensed consolidated financial statements. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual results could differ from those estimates. Significant estimates on the accompanying interim unaudited condensed consolidated financial statements include the allowance for doubtful accounts, valuation of inventories, the Company’s effective income tax rate, the fair value calculations of stock-based compensation, goodwill, finite lived intangibles and the earn-out (“Earn-Out”) liability. </p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical instrument depreciation was previously reported as a component of cost of revenues in the Company’s accompanying consolidated statements of operations. Medical instruments are orthopedic devices that are utilized in all cases where our Orthopedic Implants are implanted. Subsequent to December 31, 2021, the Company began depreciating these medical instruments over 3 years and have now reclassed this depreciation expense to depreciation and amortization in the accompanying consolidated statements of operations.</p>
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	342168
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	11593832
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5665015
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9222628
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10105774
	us-gaap	Depreciation Depreciation	6992
CY2022Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1501057
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1496557
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	244647
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	179216
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1256410
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1317341
CY2021Q4	us-gaap	Goodwill Goodwill	1972886
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32715
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12633
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	65431
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25266
CY2022Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	6857
CY2021Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	6857
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1745000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.86
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1745000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.86
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1695000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.87
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1522
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	214290
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	198801
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	19481
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10027
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9186
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	10027
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9186
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0
	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10027
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9186
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1439042
CY2022Q2	fzmd	Deferred Tax Assets Accounts Receivable DeferredTaxAssetsAccountsReceivable	83090
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	559495
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	555936
CY2022Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	454371
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	20019
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1244
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2556017
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2447215
CY2022Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	194809
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	200323
CY2022Q2	fzmd	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	2341727
CY2021Q4	fzmd	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	2246892
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2246892
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1816546
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	94835
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	430346
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2341727
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2246892
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	94835
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6852583
	fzmd	Net Operating Loss Carryforwards Earliest Expiration Year NetOperatingLossCarryforwardsEarliestExpirationYear	2022
	fzmd	Net Operating Loss Carryforwards Latest Expiration Year NetOperatingLossCarryforwardsLatestExpirationYear	2038
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	fzmd	Effective Income Tax Rate Reconciliation Gain On Payroll Protection Loan EffectiveIncomeTaxRateReconciliationGainOnPayrollProtectionLoan	0.000
	fzmd	Effective Income Tax Rate Reconciliation Gain On Payroll Protection Loan EffectiveIncomeTaxRateReconciliationGainOnPayrollProtectionLoan	0.145
	fzmd	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.000
	fzmd	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.000
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.018
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.359
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.023
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.023
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	326352
	us-gaap	Net Income Loss NetIncomeLoss	-538803
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12844
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-2450216
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.014
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	13640
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	13639
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	523131
	us-gaap	Depreciation Depreciation	78613

Files In Submission

Name	View Source	Status
0001564590-22-029139-index-headers.html	Edgar Link	pending
0001564590-22-029139-index.html	Edgar Link	pending
0001564590-22-029139.txt	Edgar Link	pending
0001564590-22-029139-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fzmd-10q_20220630.htm	Edgar Link	pending
fzmd-20220630.xsd	Edgar Link	pending
fzmd-ex311_8.htm	Edgar Link	pending
fzmd-ex312_6.htm	Edgar Link	pending
fzmd-ex321_9.htm	Edgar Link	pending
ggagwtd5enhb000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
fzmd-20220630_cal.xml	Edgar Link	unprocessable
fzmd-20220630_def.xml	Edgar Link	unprocessable
fzmd-20220630_lab.xml	Edgar Link	unprocessable
fzmd-20220630_pre.xml	Edgar Link	unprocessable
fzmd-10q_20220630_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FZMD
Fuse Medical, Inc. Stock $fzmd

2022 Q3 Form 10-Q Financial Statement

#000156459022029139 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FZMD Fuse Medical, Inc. Stock $fzmd

2022 Q3 Form 10-Q Financial Statement

#000156459022029139 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FZMD
Fuse Medical, Inc. Stock $fzmd